Articles from Timeline

Timeline (Amazentis SA), the Swiss longevity biotech company behind Mitopure® (Urolithin A), today announced major scientific milestones reinforcing its position as a leader in clinically researched longevity supplements, targeting the three critical unmet needs of healthy aging: muscle, immune, and brain function.

Timeline®, a leading longevity biotech company and the maker of Mitopure®, today announced it has been named a Milestone 1 Award Winner in the prestigious XPRIZE Healthspan competition. Selected from hundreds of international teams, Timeline is one of the Top 40 global teams advancing innovative, safe, and science-backed approaches to extend healthy human function by at least a decade.

Timeline®, the Swiss consumer biotech company at the forefront of longevity research, has launched Mitopure® Gummies, a new, convenient format of its Urolithin A supplement containing a patented and pure form of this powerful postbiotic. Mitopure Gummies support cellular health by helping remove damaged mitochondria and waste (a process called mitophagy) and create new, healthy mitochondria, improving the cell’s ability to produce energy, which often translates to the body feeling stronger and more energized. It is the only supplement clinically shown to reactivate this essential biological pathway.

Regulatory News:

Timeline, a consumer health biotech company at the forefront of developing innovative solutions for healthy aging and longevity, today announces that it raised CHF 56M (USD 66M) in an oversubscribed Series D financing round. This marks a significant milestone for the company and includes strategic investments from two global industry leaders—L’Oréal and Nestlé.

On November 7th, the first global Urolithin A Scientific Summit, brought to the world stage by Timeline, is set to present paradigm-shifting research in the field of longevity. Led by experts in the scientific community, the virtual summit, open to the general public, practitioners, and scientists, will highlight the latest research in aging, particularly focusing on Urolithin A—a breakthrough postbiotic natural molecule with a meaningful impact on health.

Amazentis, an innovative Swiss health science company at the forefront of longevity research, today announced the appointment of a new Chief Executive Officer, Brian Ray.